The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration

American Journal of Respiratory Cell and Molecular Biology

Volumn 41, Issue 2, 2009, Pages 179-188

  Yasuoka, Hidekata ^a   Yamaguchi, Yukie ^a   Feghali Bostwick, Carol A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrosis; IGFBP 5; MAPK; Migration; Mononuclear cells

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL MIGRATION; CELL TRANSFORMATION; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROBLAST; LUNG FIBROSIS; LYMPHOCYTE MIGRATION; MACROPHAGE; MESENCHYME CELL; MONOCYTE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE;

ANIMALS; BIOLOGICAL MARKERS; CELL MOVEMENT; ENZYME ACTIVATION; FIBROBLASTS; FIBROSIS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR I; LEUKOCYTES, MONONUCLEAR; LUNG; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE; T-LYMPHOCYTES;

MUS;

EID: 67651162007     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2008-0211OC     Document Type: Article

References (51)

1. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-1315.
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-664.
3. Harrison NK, Myers AR, Corrin B, Soosay G, Dewar A, Black CM, Du Bois RM, Turner-Warwick M. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991;144:706-713.
4. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
5. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-2444.
6. Keogh BA, Crystal RG. Alveolitis: the key to the interstitial lung disorders. Thorax 1982;37:1-10.
7. Keane MP, Strieter RM. The importance of balanced proinflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir Res 2002;3:5-13.
8. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993;143:651-655.
9. Silver RM, Medsger TA Jr, Bolster MB. Systemic sclerosis and scleroderma variants: clinical aspects. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions. Philadelphia: Lippincott, Williams, and Wilkins; 2005. pp. 1633-1680.
10. Feghali-Bostwick CA, Tsai GS, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, Gadgil A, George MP, Gibson KF, Choi AMK, et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007;179:2592-2599.
11. Frigieri L, Mormile F, Grilli N, Mancini D, Ciappi G, Pagliari G, Magaro M, Flamini G. Bilateral bronchoalveolar lavage in progressive systemic sclerosis: interlobar variability, lymphocyte subpopulations, and functional correlations. Respiration 1991;58:132-140.
12. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56:3167-3171.
13. Flaherty KR, Travis WD, Colby TV, Towes GB, Kazerooni EA, Gross BH, Jain A, Strawerman RL III, Flint A, Lynch JP III, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:1722-1727.
14. Feghali CA, Wright TM. Identification of multiple, differentially expressed messenger RNAs in dermal fibroblasts from patients with systemic sclerosis. Arthritis Rheum 1999;42:1451-1457.
15. Pilewski JM, Liu L, Henry AC, Knauer AV, Feghali-Bostwick CA. Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol 2005;166:399-407.
16. Yasuoka H, Jukic DM, Zhou Z, Choi AMK, Feghali-Bostwick CA. Insulin-like growth factor binding protein 5 induces skin fibrosis. Arthritis Rheum 2006;54:3001-3010.
17. Yasuoka H, Zhou Z, Pilewski JM, Oury TD, Choi AMK, Feghali-Bostwick CA. Insulin-like growth factor-binding protein-5 induces pulmonary fibrosis and triggers mononuclear cell infiltration. Am J Pathol 2006;169:1633-1642.
18. Yasuoka H, Okazaki Y, Kawakami Y, Hirakata M, Inoko H, Ikeda Y, Kuwana M. Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Behcet's disease. Arthritis Rheum 2004;50:3658-3662.
19. Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR. Extracellular matrix contains Insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 1993;121:679-687.
20. Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that IGF-binding protein-5 functions as a growth factor. J Clin Invest 2001;107:73-81.
21. Kuemmerle JF, Zhou H. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by ras-dependent activation of p38 MAP kinase and Erk1/2 pathways. J Biol Chem 2002;277:20563-20571.
22. Xu Q, Yan B, Li S, Duan C. Fibronectin binds insulin-like growth factor-binding protein 5 and abolishes its ligand-dependent action on cell migration. J Biol Chem 2004;279:4269-4277.
23. Hsieh T, Gordon RE, Clemmons DR, Busby WH, Duan C. Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins. J Biol Chem 2003;44:42886-42892.
24. Abrass CK, Berfield AK, Andress DL. Heparin binding domain of insulin-like growth factor binding protein-5 stimulates mesangial cell migration. Am J Physiol 1997;273:F899-F906.
25. Wells AU, Lorimer S, Majumdar S, Harrison NK, Corrin B, Black CM, Jeffery PK, du Bois RM. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. Eur Respir J 1995;8:266-271.
26. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, Valeyre D, Soumelis V, Crestani B, Soler P. Cutting Edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006;176:5735-5739.
27. Kuwana M, Okazaki Y, Kodama H, Izumi K, Yasuoka H, Ogawa Y, Kawakami Y, Ikeda Y. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 2003;74:833-845.
28. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004;36:598-606.
29. Labat ML, Bringuier AF, Arys-Philippart C, Arys A, Wellens F. Monocytic origin of fibrosis. In vitro transformation of HLA-DR monocytes into neo-fibroblasts: inhibitory effect of all-trans retinoic acid on this process. Biomed Pharmacother 1994;48:103-111.
30. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Muller KH, Sharkey AM, Smith SK. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996;98:482-489.
31. Gordon S, Taylor PR. Monocytes and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964.
32. Kuhn C, McDonald JA. The role of the myofibroblast in idiopathic pulmonary fibrosis. Am J Pathol 1991;138:1257-1265.
33. Wu Y, Wang J, Scott PG, Tredget EE. Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen 2007;15:S18-S26.
34. Guvakova MA. Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol 2007;39:890-909.
35. Amaar YG, Baylink DJ, Mohan S. Ras-Association Domain Family 1 Protein, RASSIF1C, is an IGFBP-5 binding partner and a potential regulator of osetoblast cell proliferation. J Bone Miner Res 2005;20:1430-1439.
36. Laviola L, Natalicchil A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des 2007;13:663-669.
37. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004;117:4619-4628.
38. Ehernreiter K, Piazzolla D, Velamoor V, Sobczak I, Small JV, Takeda J, Leung T, Baccarini M. Raf-1 regulates Rho signaling and cell migration. J Cell Biol 2005;168:955-964.
39. Andress DL. Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol 1998;274:E744-E750.
40. 201-218 stimulates Cdc42GAP aggregation and filopodia formation in migrating mesangial cells. Kidney Int 2000;57:1991-2003.
41. Schneider MR, Wolf E, Hoeflich A, Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol 2002;172:423-440.
42. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998;140:19-24.
43. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998;19:568-574.
44. Hasegawa M, Sato S, Echigo T, Hamaguchi Y, Yasui M, Takehara K. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 2005;64:21-28.
45. Pantelidis P, Southcott AM, Black CM, du Bois RM. Up-regulation of IL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis; a subpopulation analysis. Clin Exp Immunol 1997;108:95-104.
46. Huaux F, Gharaee-Kerumani M, Liu T, Morel V, McGarry B, Ullenbruch M, Kunkel SL, Wang J, Xing Z, Phan SH. Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am J Pathol 2005;167:1485-1496.
47. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lung in response to CXCL12 and mediate fibrosis. J Clin Invest 2004;114:438-446.
48. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space aftrer fibrotic injury. Am J Pathol 2005;166:675-684.
49. Sahhar J, Littlejohn G, Conron M. Fibrosing alveolitis in systemic sclerosis: the need for early screening and treatment. Intern Med J 2004;34:626-638.
50. Kamp DW. Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited. Chest 2003;124:1187-1190.
51. Wynn TA. Fibrotic disease and the Th1/Th2 paradigm. Nat Rev Immunol 2004;4:583-594.